Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Appendix B: Panel Roster and Financial Disclosures

Toxoplasma gondii

Last Updated: January 1, 2020; Last Reviewed: August 1, 2019

Toxoplasma gondii Encephalitis
Member Financial Disclosure
 Company Relationship
Boyd, Sarita Food and Drug Administration None N/A
Chow, Felicia University of California, San Francisco None N/A
Kovacs, Joe*  National Institutes of Health Matinas BioPharma Research Support
Merck Research Support
Kuruppu, Janaki National Institutes of Health None N/A
Lai, Leon Washington Hospital Center None N/A
Miro, Jose M. Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain None N/A
Podzamczer, Daniel
Hospital Universitari de Bellvitge, Barcelona, Spain
None N/A
* Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the update date. The period of reporting was from August 1, 2018, through August 1, 2019

Download Guidelines